Spots Global Cancer Trial Database for Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma
Official Title: Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma
Study ID: NCT02851589
Interventions
Study Description
Brief Summary: The purpose of this study is to evaluate the safety and effectiveness of CAR-T cell immunotherapy in patients with CD19 positive relapsed or refractory Leukemia and Lymphoma.
Detailed Description:
Keywords
Eligibility
Minimum Age: 14 Years
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
PersonGen BioTherapeutics (Suzhou) Co., Ltd., Suzhou, Jiangsu, China
Contact Details
Name: Xingbing Wang, Ph.D.
Affiliation: Anhui Provincial Hospital
Role: PRINCIPAL_INVESTIGATOR
Name: Xin Liu, Ph.D.
Affiliation: Anhui Provincial Hospital
Role: PRINCIPAL_INVESTIGATOR
Name: Lin Yang, Ph.D.
Affiliation: PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
